



JC02 Rec'd PTO 03 JUN 2005 PCT
#3.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re United States Patent Application of:) Docket No.:	4121-176
Applicant(s): Terness, et al) Examiner:	Not Yet Assigned
Application No.: 10/524,168) Art Unit:	Not Yet Assigned
Date Filed: February 7, 2005) Customer No.:	
Title: GPI ANCHORED GLYCOPROTEIN ACA AS A NOVEL TUMOR MARKER)	23448

FIRST CLASS MAIL CERTIFICATE

I hereby certify that I am mailing the attached documents to the Commissioner for Patents on the date specified, in an envelope addressed to the Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, and First Class Mailed under the provisions of 37 CFR 1.8.



Joanna Joslyn

May 31, 2005

Date of Mailing

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO/SB/08A. One copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

- 1. This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No certification or fee is required.
- 2. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.

a. I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1).

b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(2).

c. Attached is our check no. _____ in the amount of \$_____ in payment of the fee under 37 C.F.R. §1.17(p). Please credit or debit Deposit Account No. _____ as needed to ensure consideration of the disclosed information. Two duplicate copies of this paper are attached.

3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. Applicant(s) hereby petition(s) that the Information Disclosure Statement be considered. Attached is our check no. _____ in the amount of \$180.00 in payment of the petition fee under 37 C.F.R. §1.17(p). Please credit or debit Deposit Account No. _____ as needed to ensure consideration of the disclosed information. Two duplicate copies of this paper are attached.

a. I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1).

b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(2).

Respectfully submitted,



Marianne Fuierer
Reg. No. 39,983
Attorney for Applicant

INTELLECTUAL PROPERTY/
TECHNOLOGY LAW
Telephone: (919) 419-9350
Fax: (919) 419-9354
Attorney Ref: 4121-176



**INFORMATION
DISCLOSURE STATEMENT
BY APPLICANT**

Sheet 1 of 1

COMPLETE IF KNOWN	
Application Number	10/524,168
Filing Date	February 7, 2005
First Named Inventor	TERNESS, et al.
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	4121-176

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AA	BECKER KOJIC, et al., "A Novel Human Erythrocyte Glycosylphosphatidylinositol (GPI) anchored Glycoprotein ACA," <i>The Journal of Biological Chemistry</i> , Vol. 277, No. 43, Pages 40472-40478, October 25, 2002.	
	AB	MAYOR, et al., "Glycolipid Precursors for the Membrane Anchor of <i>Trypanosoma brucei</i> Variant Surface Glycoproteins," <i>The Journal of Biological Chemistry</i> , Vol. 265, No. 11, Pages 6174-6181, April 15, 1990.	
	AC	RUDD, et al., "The Glycosylation of the Complement Regulatory Protein, Human Erythrocyte CD59," <i>The Journal of Biological Chemistry</i> , Vol. 272, No. 11, Pages 7229-7244, March 14, 1997.	
	AD	McCONVILLE, et al., "The Structure, Biosynthesis and Function of Glycosylated Phosphatidylinositol in the Parasitic Protozoa and Higher Eukaryotes," <i>Biochem J.</i> , Vol. 294, Pages 305-324, 1993.	
	AE	CHEN, et al., "Mammalian Glycophosphatidylinositol Anchor Transfer to Proteins and Posttransfer Deacylation," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 95, Pages 9512-9517, August 1998.	

Examiner signature	Date Considered
--------------------	-----------------

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

² Applicant is to place a check mark here if English Translation is attached. All the foreign patents and publications that are not written in English language are accompanied by their respective English abstracts, which constitute concise explanation of relevance of the non-English patents and publications that satisfy the requirements of 37 C.F.R. §1.98(a)(3)(i), according to MPEP 609 III A(3).